CytokineticsCYTK
CYTK
About: Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Employees: 564
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
81% more call options, than puts
Call options by funds: $280M | Put options by funds: $154M
47% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 96
7% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 43
0% more funds holding
Funds holding: 343 [Q2] → 343 (+0) [Q3]
3% less capital invested
Capital invested by funds: $7.46B [Q2] → $7.21B (-$245M) [Q3]
12.31% less ownership
Funds ownership: 131.31% [Q2] → 119.0% (-12.31%) [Q3]
25% less funds holding in top 10
Funds holding in top 10: 20 [Q2] → 15 (-5) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$72
42%
upside
Avg. target
$89
76%
upside
High target
$120
136%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 27% 1-year accuracy 110 / 403 met price target | 136%upside $120 | Buy Reiterated | 22 Jan 2025 |
Stifel James Condulis 100% 1-year accuracy 1 / 1 met price target | 58%upside $80 | Buy Initiated | 22 Jan 2025 |
JMP Securities Jason Butler 33% 1-year accuracy 14 / 42 met price target | 54%upside $78 | Market Outperform Reiterated | 14 Jan 2025 |
RBC Capital Leonid Timashev 40% 1-year accuracy 18 / 45 met price target | 62%upside $82 | Outperform Maintained | 18 Dec 2024 |
Needham Serge Belanger 41% 1-year accuracy 53 / 130 met price target | 42%upside $72 | Buy Reiterated | 2 Dec 2024 |
Financial journalist opinion
Based on 7 articles about CYTK published over the past 30 days
Negative
Zacks Investment Research
3 days ago
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Positive
Benzinga
4 days ago
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company's catalyst rich one to two years.
Neutral
GlobeNewsWire
5 days ago
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy.
Neutral
GlobeNewsWire
1 week ago
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
PDUFA Target Action Date for Aficamten Set for September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval
Neutral
GlobeNewsWire
2 weeks ago
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.
Neutral
GlobeNewsWire
3 weeks ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,189 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 9 employees, whose employment commenced in December 2024, as a material inducement to their employment.
Positive
Seeking Alpha
3 weeks ago
Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution
Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US commercialization. Clinical trials aim to expand aficamten's utility, including first-line and pediatric indications.
Neutral
GlobeNewsWire
1 month ago
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).
Positive
The Motley Fool
1 month ago
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in a key market abroad was the catalyst for the increase, which well exceeded the slightly over 1% gain of the S&P 500 index.
Neutral
GlobeNewsWire
1 month ago
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM.
Charts implemented using Lightweight Charts™